Evaluation of Targeted Biopsy Plus Sextant Biopsy in Diagnosis of Prostate Cancer

Recruiting N/A Interventional Study
Prostate Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
45 – 85
Sex
Male
Study type
Interventional
Purpose
Diagnostic
Participants needed
300 (estimated)
Sponsor
Peking University First Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this randomized controlled trial (RCT) is to evaluate the efficacy and safety of different prostate biopsy schemes, including targeted biopsy plus sextant biopsy (3TB+6SB) and combination of targeted biopsy and 12-core systematic biopsy (3TB+12SB). The main questions it aims to answer are: Does 3TB+6SB promote the accurate diagnosis of clinically significant prostate cancer? What's t…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * The age of the patient is between 45 and 85 years. * No previous biopsy. * Patients with single suspicious lesion, complete multiparametric magnetic resonance imaging (mpMRI) data, qualified image quality control, suspicious lesions, and Prostate Imaging Reporting and Data Sys…
Contacts

Yi Liu

+86 13611035261

liuyipkuhsc@163.com

CONTACT